TranslatePriority 18 from the Myeloma (Canada) PSP
| UNCERTAINTY: What is the risk to blood relatives of people with myeloma, and should they be monitored or tested routinely? (JLA PSP Priority 18) | |
|---|---|
| Overall ranking | 18 |
| JLA question ID | 0113/18 |
| Explanatory note | Participants wanted research into the risk of developing myeloma for family members of persons with myeloma. Many reported relatives who also had the disease. Patients wondered about the risk to their children and wondered whether they should be monitored or tested routinely. |
| Evidence |
No evidence identified |
| Health Research Classification System category | Cancer and neoplasms |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | Is there a significant familial clustering of myeloma? ~ Are there benefits to early intervention in cases where there is significant family history of the disease? ~ Should my family be tested for it? ~ Do our children need to be monitored more closely? ~ Can we consider screening the adult children of MM patients at a certain age? ~ Are family members at risk to develop? ~ How can my family prevent it? ~ Is there a test to be given family members to see if they are at risk? ~ Can my children be tested for the cancer? |
| Submitted by | Please see the PSP Engagement Summary on the JLA website |
| PSP information | |
|---|---|
| PSP unique ID | 0113 |
| PSP name | Myeloma (Canada) |
| Total number of uncertainties identified by this PSP. | 59 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 28 April 2021 |
